Feasibility and utility of a panel testing for 114 cancer-associated genes in a clinical setting: A hospital-based study

Kuniko Sunami, Hitoshi Ichikawa, Takashi Kubo, Mamoru Kato, Yutaka Fujiwara, Akihiko Shimomura, Takafumi Koyama, Hiroki Kakishima, Mayuko Kitami, Hiromichi Matsushita, Eisaku Furukawa, Daichi Narushima, Momoko Nagai, Hirokazu Taniguchi, Noriko Motoi, Shigeki Sekine, Akiko Maeshima, Taisuke Mori, Reiko Watanabe, Masayuki YoshidaAkihiko Yoshida, Hiroshi Yoshida, Kaishi Satomi, Aoi Sukeda, Taiki Hashimoto, Toshio Shimizu, Satoru Iwasa, Kan Yonemori, Ken Kato, Chigusa Morizane, Chitose Ogawa, Noriko Tanabe, Kokichi Sugano, Nobuyoshi Hiraoka, Kenji Tamura, Teruhiko Yoshida, Yasuhiro Fujiwara, Atsushi Ochiai, Noboru Yamamoto, Takashi Kohno

Research output: Contribution to journalArticlepeer-review

114 Citations (Scopus)

Abstract

Next-generation sequencing (NGS) of tumor tissue (ie, clinical sequencing) can guide clinical management by providing information about actionable gene aberrations that have diagnostic and therapeutic significance. Here, we undertook a hospital-based prospective study (TOP-GEAR project, 2nd stage) to investigate the feasibility and utility of NGS-based analysis of 114 cancer-associated genes (the NCC Oncopanel test). We examined 230 cases (comprising more than 30 tumor types) of advanced solid tumors, all of which were matched with nontumor samples. Gene profiling data were obtained for 187 cases (81.3%), 111 (59.4%) of which harbored actionable gene aberrations according to the Clinical Practice Guidelines for Next Generation Sequencing in Cancer Diagnosis and Treatment (Edition 1.0) issued by 3 major Japanese cancer-related societies. Twenty-five (13.3%) cases have since received molecular-targeted therapy according to their gene aberrations. These results indicate the utility of tumor-profiling multiplex gene panel testing in a clinical setting in Japan. This study is registered with UMIN Clinical Trials Registry (UMIN 000011141).

Original languageEnglish
Pages (from-to)1480-1490
Number of pages11
JournalCancer science
Volume110
Issue number4
DOIs
Publication statusPublished - 2019 Apr
Externally publishedYes

Keywords

  • actionable gene aberration
  • clinical sequencing
  • gene panel test
  • insurance reimbursement
  • NCC Oncopanel

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Feasibility and utility of a panel testing for 114 cancer-associated genes in a clinical setting: A hospital-based study'. Together they form a unique fingerprint.

Cite this